New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
18:40 EDTTGTX, CYS, CMG, UCTT, JNJ, CNI, SANM, RMBS, APA, HLX, NFLX, TEPOn The Fly: After Hours Movers
UP AFTER EARNINGS: Netflix (NFLX), up marginally after reporting Q2 results... Sanmina (SANM), up 13.2% after reporting third quarter results and fourth quarter guidance above analyst estimates... Chipotle (CMG), up 10.1%... Helix (HLX), up 5.2%... Canadian National (CNI), up 1.13%... CYS Investments (CYS), up 1.7%. ALSO HIGHER: Apache (APA), up 5% after Bloomberg says JANA discloses $1B position... Johnson & Johnson (JNJ), up 1% after announcing a $5B share repurchase program... TG Therapeutics (TGTX), up 4.3% after reporting second quarter results and preliminary clinical results from TG-1101 Phase I study... DOWN AFTER EARNINGS: Rambus (RMBS), down 3.6% after reporting second quarter results... Ultra Clean (UCTT), down 4% after reporting quarterly results. ALSO LOWER: Tallgrass Energy (TEP), down 5% after filing to sell 7M common units representing limited partners.
News For NFLX;SANM;CMG;HLX;CNI;CYS;APA;JNJ;TGTX;RMBS;UCTT;TEP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
January 20, 2015
16:07 EDTNFLXNetflix sees Q1 net streaming additions of 4.05M
Subscribe for More Information
16:06 EDTNFLXNetflix sees Q1 EPS 60c, consensus 77c
Subscribe for More Information
16:06 EDTNFLXNetflix reports 4.33M members added in Q4
Subscribe for More Information
16:00 EDTJNJ, NFLXOptions Update; January 20, 2015
iPath S&P 500 VIX Short-Term Futures down 36c to 35.12 Option volume leaders: AAPL TSLA TWTR GILD NFLX MGM ABX AMAT JNJ C according to Track Data.
15:21 EDTNFLXNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include IBM (IBM), consensus $5.41; Netflix (NFLX), consensus 45c; CA Technologies (CA), consensus 60c; Cree (CREE), consensus 22c; Woodward (WWD), consensus 46c; Fulton Financial (FULT), consensus 21c; Advanced Micro Devices (AMD), consensus 1c; Interactive Brokers (IBKR), consensus 6c; Pinnacle Financial (PNFP), consensus 53c.
14:17 EDTNFLXNetflix technical commentary ahead of earnings
The stock has been in a sideways consolidation pattern since a sharp downtrend began in October of last year. The approximate range has been a high at $350 and a low at $320. Breaks of either end of this range will be important determinants of the trend following earnings. A breakout above $350 would potentially reverse the current dominant downtrend. With over 8.5% of the trading float short, there could be substantial buy-to-cover pressure in the event of a positive surprise. Upside levels to watch above $350 would be at $357.95, $366.51, and $375.83. On an extreme positive surprise, the $380 area could be tested. If the news is negative, a break below the $320 area would likely lead to a resumption of the dominant downtrend. Support levels to watch would be at $310.25, $299.50, and $290.28. A breakdown below $300 would be long-term bearish for price, confirming a major top.
14:04 EDTNFLXNetflix January weekly 345 straddle priced for 11% movement into Q4
Subscribe for More Information
13:08 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
10:33 EDTJNJJohnson & Johnson falls post-earnings, levels to watch
Subscribe for More Information
09:48 EDTJNJJohnson & Johnson says eyeing options in orthopedics, surgical, vision care
Subscribe for More Information
09:21 EDTJNJJ&J says negative impact of currency to be 'more significant' than expected
Says currency impact will be more significant in 1H than in 2H.
09:20 EDTJNJJ&J says 'comfortable' with models reflecting midpoint of FY EPS view
Subscribe for More Information
09:18 EDTJNJJohnson & Johnson sees FY15 reported sales $75B-$76B
Subscribe for More Information
09:18 EDTJNJJohnson & Johnson CEO says core businesses 'strong'
Johnson & Johnson (JNJ) providing sustainable, high quality healthcare "one of society's greatest challenges." Says core businesses "strong," positioned to continue expanding their leadership positions. CEO Alex Gorsky says company is changing the way it interacts with customers, evolving to be more "effective," "efficient." Says U.S. OTC consent decree requirements completed. Says in the process of developing a China lung center. Says still plans to take $1B out of P&L in next three years. Says aims to bring Ebola vaccine to market "as fast as possible." Says "well-positioned" for long-term. Says currency headwinds have increased "quite substantially," negatively impacting sales, earnings to greater extent than company had anticipated. Sees Depomed (DEPO) transaction closing in Q2. Expects R&D tax credit will be renewed in 2015. If R&D tax credit is approved, sees effective tax rate for 2015 of approx. 20%-21%. Sees operational sales growth for 2015 approx. 6%. Says Wall Street forecasts may not adequately reflect likely negative impact in 2015 of foreign exchange. Sees FY15 operational sales growth 1%-2% in constant currency. Comments made on the Q4 earnings conference call.
08:18 EDTJNJJohnson & Johnson sees 10 major Pharmaceuticals filings from 2013-2017
Sees 10 major filings, 25 line extensions in Pharmaceuticals expected between 2013-2017. Sees about 100 ongoing discovery projects, 50 novel compounds in early development, 5 breakthrough designations. Sees 30 major Medical Devices filings expected from 2014-2016, 20 key Consumer product launches expected global in 2015. Says near-term priorities include: Accelerating growth in Medical Devices through innovation, expanding market leadership in key consumer segments like OTC, Oral Care, Baby and Beauty. Comments from slides that will be presented on the Q4 earnings conference call.
08:11 EDTNFLXNetflix volatility increases into Q4 and outlook
Subscribe for More Information
08:06 EDTAPAApache Chairman and CEO Farris to retire, Christmann to succeed as CEO
Subscribe for More Information
07:52 EDTJNJJohnson & Johnson reports Q4 Pharmaceutical sales $8B
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson sees FY15 adjusted EPS $6.12-$6.27, consensus $6.13
Subscribe for More Information
07:46 EDTJNJJohnson & Johnson reports Q4 EPS ex-items $1.27, consensus $1.26
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use